IBIO, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IBIO, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $9.32M.
- IBIO, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $4.82M, a 327.13% increase year-over-year.
- IBIO, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $3.65M.
- IBIO, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $219.00K, a 5375.00% increase year-over-year.
- IBIO, INC. stock issued during period, value, new issues for fiscal 2026 was $18.01M, a 393.94% increase from fiscal 2025.
- IBIO, INC. stock issued during period, value, new issues for fiscal 2025 was $3.65M, a 85.49% decline from fiscal 2024.
- IBIO, INC. stock issued during period, value, new issues for fiscal 2024 was $25.13M, a 114.93% increase from fiscal 2023.
- IBIO, INC. stock issued during period, value, new issues for fiscal 2023 was $11.69M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $9.32M derived: 10-K 12 month − 3 quarters · filed 2026-08-28 | $18.01M 10-K · filed 2026-08-28 |
| 2026-03-31 | $4.82M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $3.65M 10-Q · filed 2026-05-12 | |
| 2025-09-30 | $219.00K 10-Q · filed 2026-05-12 | |
| 2025-06-30 | $3.65M 10-K · filed 2026-08-28 | |
| 2025-03-31 | $1.13M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | -$1.00K 10-Q · filed 2026-05-12 | |
| 2024-09-30 | $4.00K 10-Q · filed 2026-05-12 | |
| 2024-06-30 | $25.13M 10-K · filed 2025-09-05 | |
| 2024-03-31 | $18.38M 10-Q · filed 2025-05-02 | |
| 2023-12-31 | $3.75M 10-Q · filed 2025-05-02 | |
| 2023-09-30 | $2.81M 10-Q · filed 2025-05-02 | |
| 2023-06-30 | $11.69M 10-K/A · filed 2024-09-24 | |
| 2019-06-30 | $0.00 10-K · filed 2020-10-13 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-15 | |
| 2018-03-31 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-11 | |
| 2017-12-31 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-14 | |
| 2017-09-30 | $1.00M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-15 | $6.22M 10-K · filed 2017-09-15 |
| 2015-06-30 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13 | $10.00M 10-K · filed 2016-10-13 |
| 2015-03-31 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-15 | |
| 2014-06-30 | $3.10M 10-K · filed 2015-10-13 | |
| 2013-06-30 | $3.83M 10-K · filed 2014-09-29 | |
| 2012-06-30 | $9.04M 10-K/A · filed 2012-10-15 | |
| 2011-06-30 | $8.00M 10-K/A · filed 2012-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |